{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Saline+Infusion&page=3", "query": { "intervention": "Placebo Comparator: Saline Infusion", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 903, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Saline+Infusion&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Saline+Infusion&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T18:52:22.160Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04634162", "title": "PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Cangrelor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-02-09", "completion_date": "2021-11-30", "has_results": true, "last_update_posted_date": "2023-05-16", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634162" }, { "nct_id": "NCT07300982", "title": "Studies of Insulin and Glucagon Action in the Liver", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes (DM)" ], "interventions": [ { "name": "Glucagon", "type": "DRUG" }, { "name": "Saline (placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 40, "start_date": "2026-10", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07300982" }, { "nct_id": "NCT00409188", "title": "Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25)", "type": "BIOLOGICAL" }, { "name": "Single low dose cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1513, "start_date": "2007-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 49, "location_summary": "Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409188" }, { "nct_id": "NCT04501978", "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "LY3819253", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "BIOLOGICAL" }, { "name": "VIR-7831", "type": "BIOLOGICAL" }, { "name": "BRII-196/BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442", "type": "BIOLOGICAL" }, { "name": "MP0420", "type": "DRUG" }, { "name": "PF-07304814", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2753, "start_date": "2020-08-04", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 98, "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501978" }, { "nct_id": "NCT02471040", "title": "Brain Ketone Metabolism in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes", "Hypoglycemia" ], "interventions": [ { "name": "Beta-hydroxybutyrate", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2013-05-14", "completion_date": "2022-04-04", "has_results": false, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471040" }, { "nct_id": "NCT00608231", "title": "Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson's Disease", "Essential Tremor", "Dystonia" ], "interventions": [ { "name": "Dexmedetomidine Hydrochloride Infusion", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2014-07-01", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608231" }, { "nct_id": "NCT07608562", "title": "Azithromycin for Cerclage Prophylaxis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cervical Insufficiency" ], "interventions": [ { "name": "Azithromycin Prophylaxis", "type": "DRUG" }, { "name": "Azithromycin Placebo", "type": "DRUG" }, { "name": "Cefazolin", "type": "DRUG" }, { "name": "Progesterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2026-09", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 2, "location_summary": "Oak Lawn, Illinois • Park Ridge, Illinois", "locations": [ { "city": "Oak Lawn", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07608562" }, { "nct_id": "NCT02508753", "title": "Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "CXA-101/tazobactam", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 52, "start_date": "2010-06", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2017-01-26", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02508753" }, { "nct_id": "NCT04428372", "title": "MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemodialysis Complication", "Hemodynamic Instability" ], "interventions": [ { "name": "Mannitol", "type": "DRUG" }, { "name": "0.9% saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-04-06", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428372" }, { "nct_id": "NCT01662895", "title": "High-Dose Deferoxamine in Intracerebral Hemorrhage", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [ { "name": "Deferoxamine", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2013-03-18", "completion_date": "2018-05-10", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-10-13T18:52:22.160Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662895" } ] }